These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36819192)

  • 21. Influence of de novo donor-specific antibody on early renal allograft function recovery.
    Zheng J; Xue W; Jing X; Hou J; Tian X; Tian P; Ding X; Pan X; Yan H; Feng X; Xiang H; Li Y; Ding C
    Ren Fail; 2015 Apr; 37(3):462-8. PubMed ID: 25697229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of HLA-matching and anti-HLA antibodies in heart transplant patients receiving induction therapy?
    Gavroy B; Timmermans T; Van Caenegem O; Mastrobuoni S; Jacquet L; Latinne D; Poncelet AJ
    Transpl Immunol; 2022 Dec; 75():101706. PubMed ID: 36113729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study.
    Fujiyama N; Satoh S; Saito M; Numakura K; Inoue T; Yamamoto R; Saito T; Kanda S; Narita S; Mitobe Y; Habuchi T
    Clin Exp Nephrol; 2019 Dec; 23(12):1398-1406. PubMed ID: 31493185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
    Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
    Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
    Ginevri F; Nocera A; Comoli P; Innocente A; Cioni M; Parodi A; Fontana I; Magnasco A; Nocco A; Tagliamacco A; Sementa A; Ceriolo P; Ghio L; Zecca M; Cardillo M; Garibotto G; Ghiggeri GM; Poli F
    Am J Transplant; 2012 Dec; 12(12):3355-62. PubMed ID: 22959074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.
    Mangiola M; Marrari M; Feingold B; Zeevi A
    Front Immunol; 2017; 8():4. PubMed ID: 28191005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
    Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
    Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch epitope load predicts de novo-DSA-free survival in pediatric liver transplantation.
    Shin S; Lee M; Dente E; Yazigi N; Khan KM; Kaufman SS; Ahn J; Timofeeva OA; Ekong UD
    Pediatr Transplant; 2022 Jun; 26(4):e14251. PubMed ID: 35279919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
    Schluckebier D; Cousin VL; Petit LM; Belli D; Wildhaber B; Rougemont AL; Villard J; Ferrari-Lacraz S; McLin VA
    Pediatr Transplant; 2020 Feb; 24(1):e13611. PubMed ID: 31682057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
    Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Follow-Up of Renal Transplant Recipients Treated With IVIG for De Novo Donor-Specific Antibodies.
    Knight RJ; Loucks-Devos J; Khan NA; Nguyen DT; Graviss EA; Eagar TN; Patel SJ; Osama Gaber A
    Transplant Proc; 2021; 53(6):1865-1871. PubMed ID: 34247857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients.
    Kim JJ; Balasubramanian R; Michaelides G; Wittenhagen P; Sebire NJ; Mamode N; Shaw O; Vaughan R; Marks SD
    Am J Transplant; 2014 Oct; 14(10):2350-8. PubMed ID: 25167892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation.
    Grabhorn E; Binder TM; Obrecht D; Brinkert F; Lehnhardt A; Herden U; Peine S; Nashan B; Ganschow R; Briem-Richter A
    Transplantation; 2015 Sep; 99(9):1876-81. PubMed ID: 25706279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.